Show simple item record

dc.contributor.authorErogbogbo, F
dc.contributor.authorMay, J
dc.contributor.authorSwihart, M
dc.contributor.authorPrasad, P
dc.contributor.authorSmart, K
dc.contributor.authorJack, S
dc.contributor.authorKorcyk, D
dc.contributor.authorWebster, M
dc.contributor.authorStewart, R
dc.contributor.authorZeng, I
dc.contributor.authorJullig, M
dc.contributor.authorBakeev, K
dc.contributor.authorJamieson, M
dc.contributor.authorKasabov, N
dc.contributor.authorGopalan, B
dc.contributor.authorLiang, L
dc.contributor.authorHu, R
dc.contributor.authorSchliebs, S
dc.contributor.authorVillas-Boas, S
dc.contributor.authorGladding, P
dc.date.accessioned2014-03-21T00:47:02Z
dc.date.available2014-03-21T00:47:02Z
dc.date.copyright2013
dc.date.issued2014-03-21
dc.identifier.citationTheranostics, vol.3(9), pp.719 - 728
dc.identifier.urihttp://hdl.handle.net/10292/6999
dc.description.abstractMetabolomic profiling is ideally suited for the analysis of cardiac metabolism in healthy and diseased states. Here, we show that systematic discovery of biomarkers of ischemic preconditioning using metabolomics can be translated to potential nanotheranostics. Thirty-three patients underwent percutaneous coronary intervention (PCI) after myocardial infarction. Blood was sampled from catheters in the coronary sinus, aorta and femoral vein before coronary occlusion and 20 minutes after one minute of coronary occlusion. Plasma was analysed using GC-MS metabolomics and iTRAQ LC-MS/MS proteomics. Proteins and metabolites were mapped into the Metacore network database (GeneGo, MI, USA) to establish functional relevance. Expression of 13 proteins was significantly different (p<0.05) as a result of PCI. Included amongst these was CD44, a cell surface marker of reperfusion injury. Thirty-eight metabolites were identified using a targeted approach. Using PCA, 42% of their variance was accounted for by 21 metabolites. Multiple metabolic pathways and potential biomarkers of cardiac ischemia, reperfusion and preconditioning were identified. CD44, a marker of reperfusion injury, and myristic acid, a potential preconditioning agent, were incorporated into a nanotheranostic that may be useful for cardiovascular applications. Integrating biomarker discovery techniques into rationally designed nanoconstructs may lead to improvements in disease-specific diagnosis and treatment.
dc.publisherIvyspring International Publisher
dc.relation.urihttp://dx.doi.org/10.7150/thno.5010
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
dc.subjectMetabolomics
dc.subjectSilicon quantum dots
dc.subjectTheranostics
dc.subjectCardiac ischemia
dc.subjectMyocardial infarction
dc.titleBioengineering silicon quantum dot theranostics using a network analysis of metabolomic and proteomic data in cardiac ischemia
dc.typeJournal Article
dc.rights.accessrightsOpenAccess
dc.identifier.doi10.7150/thno.5010
aut.relation.endpage728
aut.relation.issue9
aut.relation.startpage719
aut.relation.volume3
pubs.elements-id156913


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record